Abstract: Pharmaceutical complexes composed of drug molecules entrapped in cyclodextrin-based MOFs (CD-MOFs) are provided. Pharmaceutical tablets incorporating crystals of the pharmaceutical complexes for oral administration to a patient are also provided. In addition, methods of making the pharmaceutical complexes using anion-exchange reactions and methods of making the pharmaceutical complexes based on the co-crystallization of the drug molecules with cyclodextrin are provided. The pharmaceutical complexes include a CD-MOF and deprotonated drug anions associated with alkali metal cations in the CD-MOF superstructure.

Abstract: A separation medium consisting of a cyclodextrin metal-organic framework (CD-MOF) for separating aromatic compounds and methods of preparing the same are presented. Bottom-up preparations include the following steps: (a) preparing a first mixture comprising a cyclodextrin, an alkali metal salt, water and an alcohol; (b) performing one of the following two steps: (i) stirring the first mixture; or (ii) adding an amount of a surfactant to the first mixture to form a second mixture; and (c) crystallizing the CD-MOF from the first mixture or the second mixture. Top-down preparations include the following steps: (a) preparing a first mixture comprising the cyclodextrin, an alkali metal salt, water and an alcohol; (b) crystallizing the CD-MOF from the first mixture; and (c) optionally performing particle size reduction of the crystallized CD-MOF. The CD-MOFs are amenable for use in methods for separating alkylaromatic and haloaromatic compounds from a mixture of hydrocarbons.

Abstract: Methods of making diazaperopyrenium dications with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, and uses thereof are provided.

Abstract: A separation medium consisting of a cyclodextrin metal-organic framework (CD-MOF) for separating aromatic compounds and methods of preparing the same are presented. Bottom-up preparations include the following steps: (a) preparing a first mixture comprising a cyclodextrin, an alkali metal salt, water and an alcohol; (b) performing one of the following two steps: (i) stirring the first mixture; or (ii) adding an amount of a surfactant to the first mixture to form a second mixture; and (c) crystallizing the CD-MOF from the first mixture or the second mixture. Top-down preparations include the following steps: (a) preparing a first mixture comprising the cyclodextrin, an alkali metal salt, water and an alcohol; (b) crystallizing the CD-MOF from the first mixture; and (c) optionally performing particle size reduction of the crystallized CD-MOF. The CD-MOFs are amenable for use in methods for separating alkylaromatic and haloaromatic compounds from a mixture of hydrocarbons.

Abstract: Pharmaceutical complexes composed of drug molecules entrapped in cyclodextrin-based MOFs (CD-MOFs) are provided. Pharmaceutical tablets incorporating crystals of the pharmaceutical complexes for oral administration to a patient are also provided. In addition, methods of making the pharmaceutical complexes using anion-exchange reactions and methods of making the pharmaceutical complexes based on the co-crystallization of the drug molecules with cyclodextrin are provided. The pharmaceutical complexes include a CD-MOF and deprotonated drug anions associated with alkali metal cations in the CD-MOF superstructure.

Abstract: Methods of making diazaperopyrenium dications with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, and uses thereof are provided.